S&P 500   4,074.84 (+1.67%)
DOW   32,584.60 (+1.12%)
QQQ   304.74 (+2.11%)
AAPL   148.61 (+2.11%)
MSFT   264.94 (+1.32%)
FB   201.97 (+0.96%)
GOOGL   2,321.75 (+1.44%)
AMZN   2,268.88 (+2.38%)
TSLA   757.20 (+4.53%)
NVDA   180.01 (+4.27%)
BABA   90.79 (+4.98%)
NIO   16.57 (+13.88%)
AMD   102.69 (+8.97%)
CGC   5.91 (+3.14%)
MU   73.87 (+4.82%)
T   20.47 (+0.94%)
GE   76.73 (+2.81%)
F   13.42 (+2.84%)
DIS   107.58 (+2.28%)
AMC   12.44 (+6.23%)
PFE   51.37 (+1.38%)
PYPL   78.93 (+1.65%)
NFLX   189.55 (+1.63%)
S&P 500   4,074.84 (+1.67%)
DOW   32,584.60 (+1.12%)
QQQ   304.74 (+2.11%)
AAPL   148.61 (+2.11%)
MSFT   264.94 (+1.32%)
FB   201.97 (+0.96%)
GOOGL   2,321.75 (+1.44%)
AMZN   2,268.88 (+2.38%)
TSLA   757.20 (+4.53%)
NVDA   180.01 (+4.27%)
BABA   90.79 (+4.98%)
NIO   16.57 (+13.88%)
AMD   102.69 (+8.97%)
CGC   5.91 (+3.14%)
MU   73.87 (+4.82%)
T   20.47 (+0.94%)
GE   76.73 (+2.81%)
F   13.42 (+2.84%)
DIS   107.58 (+2.28%)
AMC   12.44 (+6.23%)
PFE   51.37 (+1.38%)
PYPL   78.93 (+1.65%)
NFLX   189.55 (+1.63%)
S&P 500   4,074.84 (+1.67%)
DOW   32,584.60 (+1.12%)
QQQ   304.74 (+2.11%)
AAPL   148.61 (+2.11%)
MSFT   264.94 (+1.32%)
FB   201.97 (+0.96%)
GOOGL   2,321.75 (+1.44%)
AMZN   2,268.88 (+2.38%)
TSLA   757.20 (+4.53%)
NVDA   180.01 (+4.27%)
BABA   90.79 (+4.98%)
NIO   16.57 (+13.88%)
AMD   102.69 (+8.97%)
CGC   5.91 (+3.14%)
MU   73.87 (+4.82%)
T   20.47 (+0.94%)
GE   76.73 (+2.81%)
F   13.42 (+2.84%)
DIS   107.58 (+2.28%)
AMC   12.44 (+6.23%)
PFE   51.37 (+1.38%)
PYPL   78.93 (+1.65%)
NFLX   189.55 (+1.63%)
S&P 500   4,074.84 (+1.67%)
DOW   32,584.60 (+1.12%)
QQQ   304.74 (+2.11%)
AAPL   148.61 (+2.11%)
MSFT   264.94 (+1.32%)
FB   201.97 (+0.96%)
GOOGL   2,321.75 (+1.44%)
AMZN   2,268.88 (+2.38%)
TSLA   757.20 (+4.53%)
NVDA   180.01 (+4.27%)
BABA   90.79 (+4.98%)
NIO   16.57 (+13.88%)
AMD   102.69 (+8.97%)
CGC   5.91 (+3.14%)
MU   73.87 (+4.82%)
T   20.47 (+0.94%)
GE   76.73 (+2.81%)
F   13.42 (+2.84%)
DIS   107.58 (+2.28%)
AMC   12.44 (+6.23%)
PFE   51.37 (+1.38%)
PYPL   78.93 (+1.65%)
NFLX   189.55 (+1.63%)
NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Forecast, Price & News

$4.53
+0.27 (+6.34%)
(As of 05/17/2022 01:34 PM ET)
Add
Compare
Today's Range
$4.28
$4.55
50-Day Range
$4.26
$9.79
52-Week Range
$4.25
$24.12
Volume
43,977 shs
Average Volume
873,990 shs
Market Capitalization
$193.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.03
30 days | 90 days | 365 days | Advanced Chart
Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

G1 Therapeutics logo

About G1 Therapeutics

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
148
Year Founded
N/A

Sales & Book Value

Annual Sales
$31.48 million
Book Value
$3.38 per share

Profitability

Net Income
$-148.35 million
Net Margins
-708.20%
Pretax Margin
-704.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
39,674,000
Market Cap
$193.48 million
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/17/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

625th out of 1,423 stocks

Pharmaceutical Preparations Industry

289th out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for G1 Therapeutics
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.17. G1 Therapeutics had a negative net margin of 708.20% and a negative trailing twelve-month return on equity of 107.75%. During the same quarter in the prior year, the company posted ($0.65) earnings per share.
View G1 Therapeutics' earnings history
.

What price target have analysts set for GTHX?

6 equities research analysts have issued 12-month price targets for G1 Therapeutics' shares. Their forecasts range from $19.00 to $71.00. On average, they expect G1 Therapeutics' stock price to reach $39.33 in the next year. This suggests a possible upside of 768.3% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the following people:
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 57, Pay $215.95k)
  • Ms. Jennifer K. Moses CPA, Chief Financial Officer (Age 47, Pay $548.18k)
  • Dr. Mark A. Velleca M.D., Ph.D., Sr. Advisor & Director (Age 58, Pay $921.86k) (LinkedIn Profile)
  • Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer and Sr. VP of R&D (Age 63, Pay $581.3k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 46, Pay $601.06k)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 62)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum Ph.D., Chief Scientific Officer (Age 58)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 53)
  • Mr. Blake Jensen, VP of Quality & Compliance
What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (8.61%), BlackRock Inc. (7.73%), Fisher Asset Management LLC (5.41%), JPMorgan Chase & Co. (4.91%), Vanguard Group Inc. (4.50%) and Dimensional Fund Advisors LP (1.33%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics
.

Which institutional investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Citigroup Inc., JPMorgan Chase & Co., UBS Group AG, Golden Green Inc., Northern Trust Corp, and Qube Research & Technologies Ltd. Company insiders that have sold G1 Therapeutics company stock in the last year include James S Hanson, John E (Jack) Jr Bailey, Mark A Velleca, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Pinz Capital Management LP, Raymond James & Associates, Goldman Sachs Group Inc., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Dynamic Technology Lab Private Ltd, Graham Capital Management L.P., and Federated Hermes Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $4.53.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $193.48 million and generates $31.48 million in revenue each year. The company earns $-148.35 million in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 148 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at (919) 213-9835, via email at [email protected], or via fax at 919-741-5830.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.